NFlection Therapeutics is a biopharmaceutical company focusing on targeted treatments for rare diseases.
NFlection Therapeutics has raised $20.0M in total funding. The most recent round was Series B. The last funding was announced in June 2022.
NFlection Therapeutics's investors include F-Prime, Eight Roads Ventures, venBio Partners.
NFlection Therapeutics is headquartered in Boston, United States.
NFlection Therapeutics is a biopharmaceutical company focusing on targeted treatments for rare diseases.
NFlection Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NFlection Therapeutics — Funding & Investors." VCBacked, June 9, 2022, https://www.vcbacked.co/company/nflection-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). NFlection Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nflection-therapeutics
{{cite web |title=NFlection Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nflection-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated